Company HST5040 Patients Pipeline Platform News Careers Partnerships HemoShear’s exclusive partners are accelerating their drug discovery initiatives by leveraging our REVEAL-Tx™ disease modeling platform to identify and validate novel approaches to diseases. Fibrotic Liver Diseases, Rare Liver Disease Takeda Pharmaceutical Company Takeda Pharmaceutical Company has an exclusive partnership with HemoShear, which has generated several novel therapeutic drug targets for liver diseases, including nonalcoholic steatohepatitis (NASH)/fibrosis. These targets were shown to inhibit biological processes associated with inflammation and fibrosis that can lead to NASH, cirrhosis, and liver cancer. Analysis using REVEAL-Tx™ suggests that inhibition of these novel biological targets demonstrate disease responses that are superior to established mechanisms of fibrosis currently being targeted by other companies in clinical trials. Under the agreement, HemoShear is eligible to receive milestone payments of potentially $470 million plus royalties, and Takeda will receive the right to license and commercialize any therapeutic that results from the partnership. More information can be found in the press release here. HemoShear is also developing a new human tissue-based model of a rare liver disease using the company’s REVEAL-Tx™ Platform. This partnership will enable Takeda to interrogate their drug targets in the genetic background of human disease and accelerate the selection of lead candidates. “This new collaboration gives us the opportunity to build on [NASH] momentum and expand the reach of our combined expertise to a challenging, severe rare liver disease of high unmet need,” said Gareth Hicks, Ph.D., GI Drug Discovery Unit Head at Takeda. More information can be found in the press release here. Partnering with HemoShear HemoShear seeks strategic partners that want to accelerate their drug discovery and development. If you are interested in partnering with HemoShear, please contact us at BusinessDevelopment@hemoshear.com. Company HST5040 Patients Pipeline Platform News Careers info@hemoshear.com 501 Locust Avenue Suite 301 Charlottesville, Virginia 22902 © 2021 HemoShear Therapeutics, Inc. | Legal | Privacy | Contact